New study reinforces importance of implementing newborn screening for cystic fibrosis in Quebec
A new study led by a team from the RI-MUHC and Cystic Fibrosis Canada reinforces the benefits of newborn screening for cystic fibrosis (CF) patients. Despite the fact that newborn screening has been implemented across North America and in several European countries as a way to improve overall survival rate and health outcomes of people living with CF, it is still not available in Quebec. The findings, recently published online in the Journal of Cystic Fibrosis, add to the increasingly overwhelming evidence in favour of newborn screening as a way to improve the quality of life for patients living with this chronic disease that is still incurable. Read the interviews Dr. Larry Lands, director of Pediatric Respiratory Medicine and Cystic Fibrosis clinic at the MCH, gave to the Montreal Gazette and Métro.
Neuro researcher helps determine new criteria for early diagnosis
An international task force of researchers working under the umbrella of the International Parkinson and Movement Disorder Society has proposed new criteria for determining the onset of PD. The task force used the latest data and research knowledge from around the world to arrive at what they consider to be the most comprehensive diagnostic criteria for PD. The criteria will serve as a benchmark for a systematic approach to PD diagnosis. Until now, no objective test for PD was available, and a diagnosis could be undertaken only by a specialist in movement disorders who carried out a neurological examination and analyzed the patient’s medical history. Watch the interview Dr. Ron Postuma, co-Chair of the MDS task force, who is also a researcher in neurosciences at the RI-MUHC and at The Neuro, and associate professor in the Department of Neurology and Neurosurgery at McGill University, gave to CTV Montreal.
[view:related_content=block_2]